Quotidian Technical Highlights on Selected Biotech Stocks -- Dermira, Denali Therapeutics, Epizyme, and Five Prime Therapeutics

Monday, January 29, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 29, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on DERM, DNLI, EPZM, and FPRX which can be accessed for free by signing up to www.wallstequities.com/registration. Zacks reported that Biotech stocks have been moving north of late, largely driven by a spate of deal
news. Such deals lend financial stability to businesses and maximize shareholders' wealth, added the report. Further, more deals are expected to be signed in the biotech space, now that the US tax reform bill allows companies to repatriate cash pilling up overseas. Pre-market today, WallStEquities.com covers the following stocks: Dermira Inc. (NASDAQ: DERM), Denali Therapeutics Inc. (NASDAQ: DNLI), Epizyme Inc. (NASDAQ: EPZM), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). All you have to do is sign up today for this free limited time offer by clicking the link below.



Menlo Park, California headquartered Dermira Inc.'s shares recorded a trading volume of 871,316 shares last Friday, which was above their three months average volume of 588,240 shares. The stock finished the trading session 2.11% higher at $30.93. The Company's shares have gained 9.64% in the last month, 16.76% over the previous three months, and 10.54% over the past year. The stock is trading above its 50-day and 200-day moving averages by 17.18% and 12.42%, respectively. Furthermore, shares of Dermira, which engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the US, have a Relative Strength Index (RSI) of 73.14. Get the full research report on DERM for free by clicking below at:


Denali Therapeutics

On Friday, South San Francisco, California headquartered Denali Therapeutics Inc.'s stock ended the session 4.96% higher at $22.20. A total volume of 133,087 shares was traded. The Company's shares have surged 43.60% in the last month. Additionally, shares of Denali Therapeutics, which engages in discovering and developing therapeutics for neurodegenerative diseases in the US, are trading 23.46% above their 50-day moving average.

On January 02nd, 2018, research firm Morgan Stanley initiated an 'Overweight' rating on the Company's stock.

On January 05th, 2018, Denali Therapeutics (DNLI) and Takeda Pharmaceutical Company Limited announced that they have entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases. Each program is directed to a genetically validated target for neurodegenerative disorders, including Alzheimer's disease and other indications, and incorporates DNLI's ATV platform for increased exposure of biotherapeutic products in the brain. The free technical report on DNLI can be accessed at:



Cambridge, Massachusetts headquartered Epizyme Inc.'s stock ended the day 1.78% lower at $16.60 with a total trading volume of 317,266 shares. The Company's shares have gained 29.18% in the last month, 3.43% over the previous three months, and 68.53% over the past year. The stock is trading 24.83% and 11.13% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Epizyme, which discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the US, have an RSI of 64.62.

On January 24th, 2018, research firm Jefferies resumed its 'Buy' rating on the Company's stock, with a target price of $25 per share. Sign up for free on Wall St. Equities and claim the latest report on EPZM at:


Five Prime Therapeutics

Shares in South San Francisco, California headquartered Five Prime Therapeutics Inc. recorded a trading volume of 513,615 shares. The stock ended Friday's session 2.88% higher at $22.13. The Company's shares are trading below their 50-day moving average by 4.76%. Furthermore, shares of the Company, which focuses on the discovery and development of immuno-oncology protein therapeutics in the US, have an RSI of 48.66.  

On January 25th, 2018, Five Prime Therapeutics announced that a development milestone for cabiralizumab has been achieved, triggering a $25 million payment from Bristol-Myers Squibb Company (BMY) under the license and collaboration agreement, established in 2015, between the companies. The milestone was triggered by initiation of a multi-arm Phase-2 clinical trial (NCT03336216), sponsored by BMY, evaluating cabiralizumab and Opdivo® (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer. See the free research coverage on FPRX at:



Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-biotech-stocks----dermira-denali-therapeutics-epizyme-and-five-prime-therapeutics-300589369.html

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store